---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-004382"
form_type: "8-K"
ticker: "ORMP"
cik: "0001176309"
company_name: "ORAMED PHARMACEUTICALS INC."
filed_at: "2026-01-14T23:59:59+00:00"
generated_at: "2026-05-16T10:19:24.382767+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Oramed to transfer POD platform to Lifeward for 49.9% beneficial ownership; invests $18M in convertible notes

## Summary
- Oramed to receive up to 49.9% beneficial ownership in Lifeward via shares, pre-funded warrants, plus 4% revenue sharing on ReWalk net sales (max 10 years).
- Oramed to invest $9M initial plus $9M milestone-based in 8% senior secured convertible notes convertible at $0.45/sh with 100% warrant coverage.
- Lifeward's ReWalk and AlterG products generated $26M revenue in trailing four quarters; CEO Mark Grant has 25+ yrs diabetes experience (Medtronic, BMS).
- Transaction requires Lifeward shareholder approval for >19.99% issuance; Oramed to manage clinical trial of oral insulin capsule.
- Combines Oramed's oral drug delivery platform with Lifeward's medical robotics; Oramed retains exposure to both platforms.

## SEC filing metadata
- accession: 0001213900-26-004382
- form_type: 8-K
- ticker: ORMP
- cik: 0001176309
- company_name: ORAMED PHARMACEUTICALS INC.
- filed_at: 2026-01-14T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1176309/000121390026004382/0001213900-26-004382-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1176309/000121390026004382/ea0272889-8k_oramed.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-004382
- JSON: https://secwatch.observer/filing/0001213900-26-004382.json
- Plain text: https://secwatch.observer/filing/0001213900-26-004382.txt

## Key facts
- Material Agreements
  ORAMED PHARMACEUTICALS INC. entered into Share Purchase Agreement with Lifeward Ltd. (effective 2026-01-12).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: Lifeward Ltd.
  - Effective: 2026-01-12
  source text: On January 12, 2026, Oramed Pharmaceuticals Inc. (the “Company”) entered into that certain Share Purchase Agreement (“Share Purchase Agreement”), by and among the Company, Lifeward Ltd. (“Lifeward”) and Oratech Pharma, Inc., the Company’s wholly-owned subsidiary (“Oratech”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1176309/000121390026004382/0001213900-26-004382-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.